CatalystCorporate

KURA ONCOLOGY: 'STRONG BUY': ZIFTOMENIB AML EXPANSIONS WITH DIFFERENT REGIMENS COULD BOOST KOMZIFTI'S PROSPECTS - SEEKINGALPHA

Ziftomenib AML regimen expansions could boost Komzifti prospects, per Seeking Alpha's Strong Buy.

What changed

Ziftomenib AML regimen expansions could boost Komzifti prospects, per Seeking Alpha's Strong Buy.

Why it matters

Ziftomenib AML regimen expansions could boost Komzifti prospects, per Seeking Alpha's Strong Buy. — impact context not separately stored; see What changed.

Sources

seekingalpha